Answers are grounded in this paper and cite their sources.
Background There is no consistent approach in assessing swallowing function both in clinical or research settings. However, its significance in ensuring proper nutrition, growth/ development, and overall quality of life is undeniable. We aim to introduce a novel methodology that enhances swallowing function as an outcome measure in clinical and rare disease research and demonstrate its efficacy in Niemann-Pick Type C1 (NPC1). Methods We reviewed commonly implemented qualitative and quantitative swallowing assessments in current clinical practice, including patient/proxy/clinician reports, clinical swallowing evaluation, videofluoroscopic swallow assessment (VFSS), and post-VFSS interpretive measures [American Speech Hearing Association National Outcomes Measures Scale (ASHA-NOMS) and National Institutes of Health penetration and aspiration scale (NIH-PAS)]. Data analysis involved descriptive statistics, longitudinal statistical modeling to account for NPC1-specific covariates, and Kappa weighting correlations to determine inter-rater reliability. Results Our NPC1 cohort ( n = 120) underwent baseline and longitudinal evaluations, ( n = 269 VFSSs). We identified three statistically significant ( p < 0.05) NPC1-specific variables associated with post-VFSS interpretive measures, providing insights into disease progression and treatment effects. Inter-rater reliability correlations for ASHA-NOMS and NIH-PAS demonstrated strong agreement between two speech pathologists [ASHA-NOMS: 0.76 (95% CI 0.70-0.83); NIH-PAS: 0.88 (95% CI 0.82- 0.93)]. VFSS mean radiation dosage was calculated ( n = 129) and fell within the acceptable range declared by the American College of Radiology (263.79 ± 147.44 cGy*cm 2 ). Conclusions This comprehensive methodology successfully documented functional swallowing status with dietary modifications and aspiration risk in a rare disease cohort (NPC1). Additionally, we effectively employed this methodology to support swallowing function as a research endpoint, specifically for phenotyping and developing therapeutic interventions for rare diseases.
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: